Skip to main content

Global Breast Cancer Therapeutics Market to Exhibit 13.1% CAGR and Reach USD 55.27 Billion till 2027; Increasing Patient Population to Aid Growth in Latin America: Fortune Business Insights™

Written by Customer Service on . Posted in Mergers And Acquisitions.

Pune, India, Jan. 11, 2021 (GLOBE NEWSWIRE) — The global breast cancer therapeutics market is set to gain impetus from the ongoing research and developments to come up with state-of-the-art drugs. This information is given by Fortune Business Insights™ in a new study. The study further mentions that the market size was USD 21.58 billion in 2019 and is projected to reach USD 55.27 billion by 2027, exhibiting a CAGR of 13.1% during the forecast period.Increasing Development of State-of-the-art Products to Favor GrowthNowadays, several renowned companies are constantly launching new breast cancer therapeutics worldwide. Most of these drugs are meant for the treatment of those types of breast cancers that were previously untreatable or the available drugs were not successful for providing positive outcomes. These factors are expected to accelerate the breast cancer therapeutics market growth in the forthcoming years.However, certain severe reactions can come up while undergoing this type of cancer therapeutics, such as targeted therapies. Patients can suffer from nausea, fatigues, rashes, gastrointestinal problems, or high blood pressure. These may hinder growth.
Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/breast-cancer-therapeutics-market-100163
Hormonal Therapy Segment to Register Lower Growth in Forthcoming YearsBased on therapy, the hormonal therapy segment generated 8.3% in terms of the breast cancer therapeutics market share in 2019. It is likely to exhibit lower growth in the coming years on account of the rising availability of their generic equivalents.COVID-19 Pandemic to Affect Growth Moderately as Cancer Requires Immediate AttentionThe COVID-19 pandemic has moderately affected the growth of the breast cancer therapeutics industry worldwide as cancer is considered to be an essential condition that requires immediate medical attention. But, in some regions, there were a few postponements or cancellations of these procedures to prevent physical contact.
To get to know more about the short-term and long-term impact of COVID-19 on this market, please visit: https://www.fortunebusinessinsights.com/industry-reports/breast-cancer-therapeutics-market-100163
North America to Remain at the Forefront Stoked by Rising Awareness ProgramsRegionally, North America procured USD 10.34 billion in 2019 in terms of revenue. The rising prevalence of breast cancer, presence of numerous providers of breast cancer therapeutics, and the surging awareness of this condition are expected to augment growth in this region. The American Cancer Society, for instance, declared that the U.S. is set to experience around 276,480 new cases of invasive breast cancer in 2020.Europe, on the other hand, is likely to retain its second position fueled by the high demand for advanced and sophisticated breast cancer therapeutics. In Asia Pacific, the market would grow rapidly because of the increasing healthcare expenditure. Lastly, the Middle East & Africa and Latin America are anticipated to show robust growth on account of the rising patient population in both regions.
Quick Buy –  Breast Cancer Therapeutics Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/100163
Key Players Aim to Gain Fast Track Approvals to Compete with Their RivalsThis global market houses a large number of companies that are nowadays striving to gain fast track approvals from government healthcare agencies to distribute and market their products. Some of the others are focusing on developing unique breast cancer therapeutics to cater to the unmet demand. Below are the two latest industry developments:September 2020: Lupin introduced Lapatinib Tablets, 250 mg, after its partner Natco Pharma received approval from the USFDA. These will be used to treat patients suffering from metastatic or advanced breast cancer.November 2019: Daiichi Sankyo Company and AstraZeneca declared that their HER2-directed antibody-drug conjugate named Enhertu was approved by the USFDA. It is meant for the treatment of adult patients living with metastatic or unresectable HER2-positive breast cancer.
A list of all the renowned therapeutics providers present in this global market:Genentech (F. Hoffmann-La Roche Ltd) (South San Francisco, U.S.)Eli Lilly and Company (Indianapolis, U.S.)Novartis AG (Basel, Switzerland)AstraZeneca (Cambridge, U.K.)Pfizer Inc. (New York City, U.S.)Sanofi (Paris, France)Eisai Co. Ltd. (Tokyo, Japan)Kyowa Kirin (Tokyo, Japan)Bristol Myers Squibb (Celgene Corporation) (New York City, U.S.)Merck & Co., Inc. (Kenilworth, U.S.)Other Players
Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/breast-cancer-therapeutics-market-100163
Table of Contents:IntroductionResearch ScopeMarket SegmentationResearch MethodologyDefinitions and AssumptionsExecutive SummaryMarket DynamicsMarket DriversMarket RestraintsMarket OpportunitiesKey InsightsPrevalence of Breast Cancer, By Key Countries/Regions, 2019Regulatory Scenario by Key RegionsOverview of Current Advances in R&D for Breast Cancer TherapeuticsKey Industry DevelopmentsNew Product LaunchesGlobal Breast Cancer Therapeutics Market Analysis, Insights and Forecast, 2016-2027Key Findings / SummaryMarket Analysis, Insights and Forecast – By TherapyTargeted TherapyAbemaciclibAdo-Trastuzumab EmtansineEverolimusTrastuzumabRibociclibPalbociclibPertuzumabOlaparibOthersHormonal TherapySelective Estrogen Receptor Modulators (SERMs)Aromatase InhibitorsEstrogen Receptor Downregulators (ERDs)ChemotherapyImmunotherapyMarket Analysis, Insights and Forecast – By Cancer TypeHormone ReceptorHER+Market Analysis, Insights and Forecast – By Distribution ChannelHospital PharmaciesRetail PharmaciesOnline PharmaciesOthersMarket Analysis, Insights and Forecast – By RegionNorth AmericaEuropeAsia PacificLatin AmericaMiddle East & Africa
TOC Continued….!
Get your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/breast-cancer-therapeutics-market-100163
SECONDARY RESEARCH IS CONDUCTED TO DERIVE THE FOLLOWING INFORMATION:Details such as revenues, market share, strategies, growth rate, product & their pricing by region/country for all major companiesDetails in relation to prevalence, incidence, patient numbers, distribution of patients, average price of treatment, etc.Number of end user facilities by region/country and average annual spending or procurement of devices by type of end user facilityNumber of procedures and average price of proceduresReplacement rate and pricing of capital equipmentMarket dynamics in relation to the market under focus – Drivers, restraints, trends, and opportunitiesMarket & technological trends, new product developments, product pipeline.
Have a Look at Related Reports:Ultrasound Equipment Market Share and Global Trend By Type (Cart-based, Compact / Point-of-Care, Hand-held), By Application(Radiology, Cardiology, Gynecology), By End User(Hospitals, Clinics, Diagnostic Centers) and Geography Forecast till 2026Diabetes Monitoring Devices Market Share and Global Trend by Product (Blood Glucose Meters, Test Strips, Lancets), Distribution Channel (Institutional Sales, Retail Sales) & Geography Forecast till 2026Pulse Oximeters Market Share and Global Trend By Product Type(Fingertip Oximeters, Handheld Oximeters, Tabletop Oximeters) By End User (Hospitals, ASC’s and Clinics, Home Healthcare) and Geography Forecast till 2025Diabetes Drugs Market Share and Global Trend By Drug Class (Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors), Diabetes Type (Type 1, Type 2), Route of Administration (Oral, Subcutaneous, Intravenous), Distribution Channel (Online pharmacies, Hospital Pharmacies, Retail Pharmacies) & Geography Forecast till 2026Immunoglobulin Market Share and Global Trend By By Route of Administration (Intravenous (IV), Subcutaneous (SC)), By Indication (Primary Immunodeficiency, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Guillain-Barré Syndrome (GBS), Immune Thrombocytopenic Purpura (ITP), Multifocal Motor Neuropathy (MMN)), By Form(Liqui, Lyophilized), By End User(Hospitals, Clinics, Homecare) and Geography Forecast till 2026
About Us:Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.
Contact Us:Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune – 411045, Maharashtra, India.Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email: sales@fortunebusinessinsights.com
Fortune Business Insights™
LinkedIn | Twitter | Blogs
Press Release: https://www.fortunebusinessinsights.com/press-release/breast-cancer-therapeutics-market-9089

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.